Clinical Trial

Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition. Therefore, this study looks at the effect of semaglutide on glucose levels in the body and other information about type 2 diabetes and obesity.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-11-22; most recent amendment 2026-04-07.
Trial Details
NCT Number NCT06706284
Lead Sponsor Marzieh Salehi
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions Spinal Cord Injuries, Type 2 Diabetes
Enrollment 50 participants
Start Date 2025-04-11
Primary Completion 2028-09-01 (estimated)
Study Completion 2029-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-13